vatalanib has been researched along with aee 788 in 2 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (aee 788) | Trials (aee 788) | Recent Studies (post-2010) (aee 788) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 83 | 3 | 34 |
| Protein | Taxonomy | vatalanib (IC50) | aee 788 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.002 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.004 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.0153 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.74 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.059 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.002 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.077 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brullo, C; Musumeci, F; Radi, M; Schenone, S | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
2 other study(ies) available for vatalanib and aee 788
| Article | Year |
|---|---|
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Models, Molecular; Neoplasms; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship | 2012 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |